文献速递秋水仙碱用于慢性冠心病患者



什么方法治疗白癜风最好 http://pf.39.net/bdfyy/

文章题目:ColchicineinPatientswithChronicCoronaryDisease

研究人员:S.M.Nidorf

发表时间：.08

期刊名称：NEnglJMed

影响因子：70.67

分区：1区

核心亮点

1、Aftersigningtheinformed-consentform,eligiblepatientsenteredanopen-labelrun-inphasefor1month,duringwhichtimetheyreceived0.5mgofcolchicineoncedaily.Attheendoftheopenlabelrun-inphase,thepatientswhowereinstableconditionandhadnounacceptablesideeffects,hadadheredtotheopen-labelcolchicineregimen,andremainedwillingtocontinueparticipationwererandomlyassignedina1:1ratiotoreceive0.5mgofcolchicineoncedailyormatchingplacebo.签署知情同意书之后，符合标准的患者进入为期1个月的开放标签导入期，在此期间接受每日一次0.5mg秋水仙碱治疗。开放标签导入期结束时，对于状况稳定，未发生无法接受的副作用，遵循开放标签秋水仙碱治疗方案并且仍愿意继续参与研究的患者，我们以1∶1的比例将其随机分组，两组分别接受每日一次0.5mg秋水仙碱或匹配安慰剂治疗。

2、Amongpatientswithchroniccoronarydisease,mostofwhomwerealreadyreceivingprovensecondarypreventiontherapies,0.5mgofcolchicineoncedailyresultedina31%lowerrelativeriskofcardiovasculardeath,spontaneousmyocardialinfarction,ischemicstroke,orischemia-drivencoronaryrevascularization(theprimaryendpoint)thanplacebo,withahazardratioof0.69.Theeffectsofcolchicineappearedtobeconsistentacrosseach


转载请注明：http://www.jmvwc.com/dxtbzz/13270.html